ABBVIE INC (4AB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock
190.6 EUR
0 (0%)
We assign a fundamental rating of 5 out of 10 to 4AB. 4AB was compared to 83 industry peers in the Biotechnology industry. While 4AB is still in line with the averages on profitability rating, there are concerns on its financial health. 4AB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
4AB had positive earnings in the past year.
In the past year 4AB had a positive cash flow from operations.
In the past 5 years 4AB has always been profitable.
4AB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
4AB has a better Return On Assets (1.75%) than 72.29% of its industry peers.
4AB has a Return On Invested Capital of 15.64%. This is amongst the best in the industry. 4AB outperforms 91.57% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 4AB is in line with the industry average of 12.28%.
The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROIC | 15.64% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
4AB has a Profit Margin of 3.94%. This is in the better half of the industry: 4AB outperforms 75.90% of its industry peers.
4AB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 33.05%, 4AB belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
In the last couple of years the Operating Margin of 4AB has declined.
4AB's Gross Margin of 71.16% is fine compared to the rest of the industry. 4AB outperforms 60.24% of its industry peers.
In the last couple of years the Gross Margin of 4AB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
The number of shares outstanding for 4AB remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 4AB has more shares outstanding
Compared to 1 year ago, 4AB has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.42 indicates that 4AB is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.42, 4AB is doing good in the industry, outperforming 71.08% of the companies in the same industry.
The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
4AB has a better Debt to FCF ratio (3.49) than 78.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Altman-Z | 2.42 |
ROIC/WACC1.88
WACC8.31%
2.3 Liquidity
A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
The Current ratio of 4AB (0.72) is worse than 79.52% of its industry peers.
4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
4AB has a Quick ratio of 0.60. This is amonst the worse of the industry: 4AB underperforms 80.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 |
3. Growth
3.1 Past
The earnings per share for 4AB have decreased strongly by -12.09% in the last year.
The Earnings Per Share has been growing slightly by 2.51% on average over the past years.
Looking at the last year, 4AB shows a small growth in Revenue. The Revenue has grown by 7.40% in the last year.
The Revenue has been growing by 11.11% on average over the past years. This is quite good.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
3.2 Future
The Earnings Per Share is expected to grow by 13.69% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.42% on average over the next years.
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 23.65, the valuation of 4AB can be described as rather expensive.
77.11% of the companies in the same industry are more expensive than 4AB, based on the Price/Earnings ratio.
4AB is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.56, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 15.39 indicates a correct valuation of 4AB.
4AB's Price/Forward Earnings ratio is rather cheap when compared to the industry. 4AB is cheaper than 91.57% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (23.79), we can say 4AB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.65 | ||
| Fwd PE | 15.39 |
4.2 Price Multiples
4AB's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 4AB is cheaper than 73.49% of the companies in the same industry.
81.93% of the companies in the same industry are more expensive than 4AB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.08 | ||
| EV/EBITDA | 16.25 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 4AB does not grow enough to justify the current Price/Earnings ratio.
4AB has a very decent profitability rating, which may justify a higher PE ratio.
4AB's earnings are expected to grow with 16.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.25
PEG (5Y)9.42
EPS Next 2Y19.81%
EPS Next 3Y16.75%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.09%, 4AB has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 0.76, 4AB pays a better dividend. On top of this 4AB pays more dividend than 95.18% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, 4AB pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
5.2 History
The dividend of 4AB is nicely growing with an annual growth rate of 7.72%!
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
4AB pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
FRA:4AB (12/12/2025, 7:00:00 PM)
190.6
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.96%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap336.86B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts77.89
Price Target213.25 (11.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.09% |
Yearly Dividend5.32
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)2.13%
PT rev (3m)12.24%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)0.91%
EPS NY rev (3m)-11.53%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.65 | ||
| Fwd PE | 15.39 | ||
| P/S | 6.63 | ||
| P/FCF | 20.08 | ||
| P/OCF | 18.94 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.25 |
EPS(TTM)8.06
EY4.23%
EPS(NY)12.38
Fwd EY6.5%
FCF(TTM)9.49
FCFY4.98%
OCF(TTM)10.06
OCFY5.28%
SpS28.77
BVpS-1.27
TBVpS-44.65
PEG (NY)3.25
PEG (5Y)9.42
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | N/A | ||
| ROCE | 20.86% | ||
| ROIC | 15.64% | ||
| ROICexc | 16.59% | ||
| ROICexgc | 572.43% | ||
| OM | 33.05% | ||
| PM (TTM) | 3.94% | ||
| GM | 71.16% | ||
| FCFM | 33% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.49 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 14.25% | ||
| Cap/Sales | 1.97% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 838.33% | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | 2.42 |
F-Score7
WACC8.31%
ROIC/WACC1.88
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.28%
EPS Next 2Y19.81%
EPS Next 3Y16.75%
EPS Next 5Y13.69%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.73%
Revenue Next 2Y9.07%
Revenue Next 3Y8.57%
Revenue Next 5Y7.42%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.29%
EBIT Next 3Y15.46%
EBIT Next 5Y11.36%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 4AB.DE FAQ
What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.
What is the valuation status of ABBVIE INC (4AB.DE) stock?
ChartMill assigns a valuation rating of 5 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.
How profitable is ABBVIE INC (4AB.DE) stock?
ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ABBVIE INC (4AB.DE) stock?
The Price/Earnings (PE) ratio for ABBVIE INC (4AB.DE) is 23.65 and the Price/Book (PB) ratio is -149.57.
Can you provide the expected EPS growth for 4AB stock?
The Earnings per Share (EPS) of ABBVIE INC (4AB.DE) is expected to grow by 7.28% in the next year.